Two specialists are impressed by the preliminary findings of a randomized trial in newly diagnosed patients, but another is ...

Gilead Sciences (GILD) closed at $83.08 in the latest trading session, marking a -0.1% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.03%. Meanwhile ...

By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V ...

A group of lawmakers wants the U.S. Patent & Trademark Office and drug companies to change their approach toward handling mistakes in disclosing patent terms, because the errors can be exploited ...

The company’s shares closed yesterday at $335.26. Yee covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Amgen, and Moderna. According to TipRanks, Yee has an average ...

“Daina Graybosch has given his Hold rating due to a combination of factors surrounding Gilead Sciences’ prospects with its new drug, lenacapavir.” Daina Graybosch’s assessment of Gilead ...

Originally published by Gilead Sciences View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma.